MTOR and lung carcinoma: In addition, lung cancer cell lines harboring PIK3CA or PTEN mutations were sensitive to dual PIK3CA/mTOR inhibitors [28, 29], which raises the hope that patients with mutations in the PI3K pathway may benefit from this type of targeted therapy in the future.